Abstract: This invention is directed to an antibody construct or fragment thereof derived from an RSV-infected human, such that the antibody construct binds with specificity to RSV fusion protein antigenic region II/A with an affinity of greater than 1×10?9M. Preferably, the antibody construct is capable of neutralizing RSV strains, including at least one RSV strain that is resistant to palivizumab. The invention further relates to nucleic acids encoding the antibody construct or portions thereof, and cell lines expressing the antibody. This invention further relates to methods for producing said antibody construct, and to the use of said antibody construct for treating or preventing infection of a patient by RSV having a normal or mutated version of F protein.

Abstract: This invention is directed to an antibody construct or fragment thereof derived from an RSV-infected human, such that the antibody construct binds with specificity to RSV fusion protein antigenic region II/A with an affinity of greater than 1×10?9M. Preferably, the antibody construct is capable of neutralizing RSV strains, including at least one RSV strain that is resistant to palivizumab. The invention further relates to nucleic acids encoding the antibody construct or portions thereof, and cell lines expressing the antibody. This invention further relates to methods for producing said antibody construct, and to the use of said anti-body construct for treating or preventing infection of a patient by RSV having a normal or mutated version of F protein.

Abstract: This invention is directed to an antibody construct or fragment thereof derived from an RSV-infected human, such that the antibody construct binds with specificity to RSV fusion protein antigenic region II/A with an affinity of greater than 1×10?9 M. Preferably, the antibody construct is capable of neutralizing RSV strains, including at least one RSV strain that is resistant to palivizumab. The invention further relates to nucleic acids encoding the antibody construct or portions thereof, and cell lines expressing the antibody. This invention further relates to methods for producing said antibody construct, and to the use of said antibody construct for treating or preventing infection of a patient by RSV having a normal or mutated version of F protein.

Abstract: This invention is directed to an antibody construct or fragment thereof derived from an RSV-infected human, such that the antibody construct binds with specificity to RSV fusion protein antigenic region II/A with an affinity of greater than 1×10?9 M. Preferably, the antibody construct is capable of neutralizing RSV strains, including at least one RSV strain that is resistant to palivizumab. The invention further relates to nucleic acids encoding the antibody construct or portions thereof, and cell lines expressing the antibody. This invention further relates to methods for producing said antibody construct, and to the use of said antibody construct for treating or preventing infection of a patient by RSV having a normal or mutated version of F protein.

Abstract: The present invention includes a human monoclonal antibody specific for the alpha-toxin of S. aureus, a hybridoma producing it, nucleic acids encoding it, and host cells transfected therewith. Further, the present invention includes methods for producing the monoclonal antibody. In addition, the present invention includes pharmaceutical compositions comprising at least one antibody or at least one nucleic acid encoding the antibody. Further, the present invention includes the use of the monoclonal antibody for treating or preventing abscess formation.

Abstract: The present invention relates to assays, kits and oligonucleotides for the detection of Pseudomonas aeruginosa for a fast, sensitive and reliable detection of Pseudomonas aeruginosa in a species- and serotype-specific manner. In particular, the present invention provides an assay for the serotype-specific detection of Pseudomonas aeruginosa, a kit for the serotype-specific detection of Pseudomonas aeruginosa, as well as oligonucleotides useful in such assay or kit. The present invention further relates to the use of Pseudomonas aeruginosa serotype specific antibodies for serotype specific treatment of Pseudomonas aeruginosa infection in a patient detected for said specific Pseudomonas aeruginosa serotype with such an assay or kit.

Abstract: The present invention includes a human monoclonal antibody specific for the alpha-toxin of S. aureus, a hybridoma producing it, nucleic acids encoding it, and host cells transfected therewith. Further, the present invention includes methods for producing the monoclonal antibody. In addition, the present invention includes pharmaceutical compositions comprising at least one antibody or at least one nucleic acid encoding the antibody. Further, the present invention includes the use of the monoclonal antibody for treating or preventing abscess formation.

Abstract: The present invention relates to a human monoclonal antibody specific for the serotype IATS 01 of P. aeruginosa, and a hybridoma producing said monoclonal antibody. In addition, the present invention relates to pharmaceutical compositions comprising at least one antibody or at least one nucleic acid encoding said antibody.

Abstract: An optoelectronic sensor includes optoelectronic converter elements having photosensitive surfaces arranged in a one or two dimensional array. A transparent cover protects the photosensitive surfaces of the optoelectronic converter elements. At least one portion of the transparent cover is shaped to include a light deflecting element such as a prism which enables the optoelectronic converter elements to be exposed to light beams coming from different directions.

Abstract: Methods are provided for the selection or screening of an antibody fragment library in bacterial cells by using a Protein Fragment Complementation Assay. The invention also provides nucleic acid molecules that encode fusion proteins, which contain a first part of a reporter molecule (e.g., a DHFR or beta-lactamase fragment), a linker, and an antibody or a functional antibody fragment. The foregoing readily can be adapted for recombinant expression, through the use of vectors and host cells, for example.

Abstract: An optoelectronic sensor includes optoelectronic converter elements having photosensitive surfaces arranged in a one or two dimensional array. A transparent cover protects the photosensitive surfaces of the optoelectronic converter elements. At least one portion of the transparent cover is shaped to include a light deflecting element such as a prism which enables the optoelectronic converter elements to be exposed to light beams coming from different directions.